Selected publications

  • Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, Pejenaute Á, Kalariya M, Butcher W, Park JS, Zhu X, Sabnis S, Kumarasinghe ES, Salerno T, Kenney M, Lukacs CM, Ávila MA, Martini PGV, Fontanellas A. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018 Oct 8. doi: 10.1038/s41591-018-0199-z. [Epub ahead of print]

  • Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Review.

  • Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P. Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

  • Vasquez M, Simões I, Consuegra-Fernández M, Aranda F, Lozano F, Berraondo P. Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1. Eur J Immunol. 2017 Jul;47(7):1108-1118. doi: 10.1002/eji.201646903. Epub 2017 Jun 12. Review.

  • Alvarez-Sola G, Uriarte I, Latasa MU, Fernandez-Barrena MG, Urtasun R, Elizalde M, Barcena-Varela M, Jiménez M, Chang HC, Barbero R, Catalán V, Rodríguez A, Frühbeck G, Gallego-Escuredo JM, Gavaldà-Navarro A, Villarroya F, Rodriguez-Ortigosa CM, Corrales FJ, Prieto J, Berraondo P, Berasain C, Avila MA. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut. 2017 Oct;66(10):1818-1828. doi: 10.1136/gutjnl-2016-312975. Epub 2017 Jan 24

  • Vasquez M, Fioravanti J, Aranda F, Paredes V, Gomar C, Ardaiz N, Fernandez-Ruiz V, Méndez M, Nistal-Villan E, Larrea E, Gao Q, Gonzalez-Aseguinolaza G, Prieto J, Berraondo P. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. Oncoimmunology. 2016 Jun 29;5(8):e1196309. doi: 10.1080/2162402X.2016.1196309. eCollection 2016 Aug.

  • Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13. PubMed PMID: 23149919.

  • Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, Berraondo P. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology. 2011 Jun;53(6):1864-73. doi: 10.1002/hep.24306. Epub 2011 May 2. PubMed PMID: 21425312.

  • Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011 Jan 15;186(2):807-15. doi: 10.4049/jimmunol.1001483. Epub 2010 Dec 8. PubMed PMID: 21148040.



"The identification of new targets to potentiate immune responses to cancer is the first step toward safer and more effective antitumor drugs", Dr. Pedro Berraondo.

Contact

Contact:
Cristina López
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 6021
clopezg@unav.es